Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

ABSTRACT: The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

PROVIDER: PRJNA894244 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

Project description:The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

| PRJNA898265 | ENA

The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

Project description:Adaptive immunotherapy including bispecific T cell engagers (TCE) has shown promise in the treatment of various cancers, but clinical responses are heterogeneous and often not durable. As response to TCE is suggested to be independent of tumor recognition and T cell state, molecular determinants or mediators of primary and acquired resistance towards TCE remain poorly understood. Here, we identify conserved behaviors of bone marrow residing CD4+ and CD8+ T cells in multiple myeloma patients undergoing TCE therapy. We show that the bone marrow immune landscape reacts to TCE therapy with cell state-dependent clonal T cell expansion and herewith infer coupling of tumor recognition via MHC-I, T cell exhaustion and clinical response. While we find the abundance of exhausted-like memory CD8+ T cell clones to be associated with clinical response failure, we describe loss of target epitope and MHC class I expression as tumor-intrinsic mechanisms of acquired resistance to TCE.

2023-03-09 | GSE217245 | GEO

The Preexisting T Cell Landscape Determines Response to T Cell-Engagers Therapy

2022-10-28 | GSE216571 | GEO

DNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [scATAC-seq]

Project description:Bispecific T cell engagers targeting tumor-associated antigens and CD3 are promising novel targeted therapeutic agents for both solid and hematologic cancers. However, prolonged TCR stimulation can lead to chromatin rewiring and T cell dysfunction. Here, we investigate the combination of bispecific T cell engagers with the DNA hypomethylating agent decitabine and observe suppressed tumor growth in preclinical models. Utilizing the PSMAxCD3 bispecific antibody for the treatment of prostate carcinoma and in vivo humanized models, we catalog, at the single-cell level, the dynamics of T cell epigenetic states during bispecific therapy, and in combination with decitabine. Importantly, this combination preserves a progenitor exhausted T cell population and delays acquisition of a dysfunctional state, at both chromatin and protein levels. At the DNA methylation level, TCR stimulation in the presence of decitabine maintains a naive-like pattern in gene loci associated with T cell stemness. This study provides a rich resource for understanding the evolution of T cell states during immunotherapy and mechanistic support for combining epigenetic modifiers with bispecific T cell engagers in the clinic.

2026-06-01 | GSE310545 | GEO

DNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [BiSulfite-seq]

2026-06-01 | GSE310428 | GEO

Characterization and comparative analysis of multifunctional natural killer cell engagers (NKCEs) during antitumor responses

Project description:T cell engagers (TCEs) are transformational oncology therapies but limited in use due to the induction of cytokine release syndrome (CRS). In comparison to T cells, natural killer (NK) cells produce less cytokines upon activation, leading to the exploration of NK cell engagers (NKCEs). However, why NK cells secrete less cytokines such as tumor necrosis factor (TNF) and how NKCEs perform directly against TCEs remain unclear. Here we report that relative to T cells, NK cells have reduced trafficking and processing of TNF. Systematic development and benchmarking studies show that NKCEs can be optimized to engage multiple activating receptors and incorporate the interleukin (IL)-2, thereby increasing their potency and durability. Furthermore, comparative studies of NKCE, IL-2, and TCE therapy in animal tumor models reveal both common and different therapeutic benefits. Our results provide a blueprint for development of multifunctional NKCEs that may serve as an alternative to current TCE therapies.

2025-03-16 | GSE264122 | GEO

APOE determines cell type-specific pathological landscape of Alzheimer's disease

Project description:APOE determines cell type-specific pathological landscape of Alzheimer's disease

| PRJNA996223 | ENA

Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

Project description:Bispecific T cell engagers (TCE) targeting BCMA and CD3 induce deep hematologic responses in approximately 60% of heavily pre-treated multiple myeloma (MM) patients. Pre-treatment with iberdomide and dexamethasone reshaped the bone marrow T cell compartment, promoted infiltration of naïve T cells, and generated 100% response rates and the longest survival in subjects with high tumor burden. This was accompanied by more favorable T cell profiling, with limited expansion of regulatory T cells and exhaustion. In total, administering TCE following dexamethasone and iberdomide treatments provided deeper and more durable responses with reduced risk of CRS. Whole Bone Marrow single cell profiling of immune phenotype of untreated and treated de novo Vk murine model.

2025-08-01 | GSE302797 | GEO

Enhancing the anti-tumor efficacy of Bispecific T cell engagers via cell surface glycocalyx editing

Project description:Enhancing the anti-tumor efficacy of Bispecific T cell engagers via cell surface glycocalyx editing

| PRJNA1030938 | ENA

A 3D Tumor Spheroid Model with Robust T Cell Infiltration for Evaluating Immune Cell Engagers

Project description:A 3D Tumor Spheroid Model with Robust T Cell Infiltration for Evaluating Immune Cell Engagers

| PRJNA1257278 | ENA